Mark S. Albom

1.4k total citations
34 papers, 983 citations indexed

About

Mark S. Albom is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mark S. Albom has authored 34 papers receiving a total of 983 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 20 papers in Oncology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mark S. Albom's work include Lung Cancer Treatments and Mutations (11 papers), Cancer therapeutics and mechanisms (10 papers) and HER2/EGFR in Cancer Research (9 papers). Mark S. Albom is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Cancer therapeutics and mechanisms (10 papers) and HER2/EGFR in Cancer Research (9 papers). Mark S. Albom collaborates with scholars based in United States, Italy and France. Mark S. Albom's co-authors include Thelma S. Angeles, Bruce Ruggeri, Bruce D. Dorsey, Lisa D. Aimone, Mark A. Ator, Mangeng Cheng, Diane E. Gingrich, Weihua Wan, Rabindranath Tripathy and Arup K. Ghose and has published in prestigious journals such as Blood, The Journal of Immunology and Biochemistry.

In The Last Decade

Mark S. Albom

34 papers receiving 915 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark S. Albom United States	19	470	404	325	190	124	34	983
Timothy J. Guzi United States	16	792 1.7×	261 0.6×	538 1.7×	258 1.4×	153 1.2×	31	1.4k
Peter Drueckes Switzerland	15	727 1.5×	173 0.4×	290 0.9×	146 0.8×	87 0.7×	24	1.2k
Zhenghong Peng United States	15	526 1.1×	114 0.3×	238 0.7×	106 0.6×	71 0.6×	38	1.0k
Chris Liang United States	13	581 1.2×	239 0.6×	463 1.4×	479 2.5×	91 0.7×	36	1.1k
Ronald E. Savage United States	20	632 1.3×	150 0.4×	341 1.0×	270 1.4×	283 2.3×	43	1.3k
Vito Guagnano Switzerland	16	896 1.9×	343 0.8×	380 1.2×	135 0.7×	105 0.8×	30	1.4k
Ramesh Jayaraman Singapore	15	433 0.9×	114 0.3×	352 1.1×	86 0.5×	143 1.2×	18	898
Julian M.C. Golec United States	18	1.7k 3.6×	247 0.6×	1.1k 3.3×	97 0.5×	59 0.5×	24	2.3k
Jean Cui United States	10	518 1.1×	231 0.6×	407 1.3×	427 2.2×	103 0.8×	18	1.0k
Suzanne Leijen Netherlands	13	770 1.6×	227 0.6×	728 2.2×	93 0.5×	80 0.6×	19	1.3k

Countries citing papers authored by Mark S. Albom

Since Specialization

Citations

This map shows the geographic impact of Mark S. Albom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark S. Albom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark S. Albom more than expected).

Fields of papers citing papers by Mark S. Albom

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark S. Albom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark S. Albom. The network helps show where Mark S. Albom may publish in the future.

Co-authorship network of co-authors of Mark S. Albom

This figure shows the co-authorship network connecting the top 25 collaborators of Mark S. Albom. A scholar is included among the top collaborators of Mark S. Albom based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark S. Albom. Mark S. Albom is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mesaros, Eugen F., Thelma S. Angeles, Mark S. Albom, et al.. (2015). Piperidine-3,4-diol and piperidine-3-ol derivatives of pyrrolo[2,1-f][1,2,4]triazine as inhibitors of anaplastic lymphoma kinase. Bioorganic & Medicinal Chemistry Letters. 25(5). 1047–1052. 14 indexed citations

Mason, Jennifer L., Jean Husten, Mark S. Albom, et al.. (2012). Comparison of LanthaScreen Eu Kinase Binding Assay and Surface Plasmon Resonance Method in Elucidating the Binding Kinetics of Focal Adhesion Kinase Inhibitors. Assay and Drug Development Technologies. 10(5). 468–475. 7 indexed citations

Mason, Jennifer L., Mark S. Albom, S. N. Prasanna Murthy, et al.. (2012). Time-Resolved Fluorescence Resonance Energy Transfer as a Versatile Tool in the Development of Homogeneous Cellular Kinase Assays. Assay and Drug Development Technologies. 10(6). 551–557. 1 indexed citations

Gingrich, Diane E., Joseph G. Lisko, Mangeng Cheng, et al.. (2012). Discovery of an Orally Efficacious Inhibitor of Anaplastic Lymphoma Kinase. Journal of Medicinal Chemistry. 55(10). 4580–4593. 31 indexed citations

Learn, Keith S., Jason Wagner, Mark S. Albom, et al.. (2012). Design of 7-amino-6-chloro-3H-imidazo[4,5-b]pyridine scaffold from 5-chloro-2,4-diaminopyrimidine pharmacophore: identification of potent inhibitors of anaplastic lymphoma kinase. MedChemComm. 3(9). 1138–1138. 4 indexed citations

Cheng, Mangeng, Matthew R. Quail, Diane E. Gingrich, et al.. (2011). CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers. Molecular Cancer Therapeutics. 11(3). 670–679. 59 indexed citations

Lu, Lily, Paweł Dobrzański, Cynthia Serdikoff, et al.. (2011). A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis. Arthritis Research & Therapy. 13(2). R68–R68. 65 indexed citations

Zificsak, Craig A., Jay Theroff, Lisa D. Aimone, et al.. (2011). Methanesulfonamido-cyclohexylamine derivatives of 2,4-diaminopyrimidine as potent ALK inhibitors. Bioorganic & Medicinal Chemistry Letters. 21(13). 3877–3880. 18 indexed citations

Albom, Mark S., Thelma S. Angeles, Henry J. Breslin, et al.. (2011). 2,7-Pyrrolo[2,1-f][1,2,4]triazines as JAK2 inhibitors: Modification of target structure to minimize reactive metabolite formation. Bioorganic & Medicinal Chemistry Letters. 21(24). 7325–7330. 17 indexed citations

10.

Tripathy, Rabindranath, Robert J. McHugh, Arup K. Ghose, et al.. (2011). Pyrazolone-based anaplastic lymphoma kinase (ALK) inhibitors: Control of selectivity by a benzyloxy group. Bioorganic & Medicinal Chemistry Letters. 21(24). 7261–7264. 27 indexed citations

11.

Zificsak, Craig A., Diane E. Gingrich, Henry J. Breslin, et al.. (2011). Optimization of a novel kinase inhibitor scaffold for the dual inhibition of JAK2 and FAK kinases. Bioorganic & Medicinal Chemistry Letters. 22(1). 133–137. 18 indexed citations

12.

Albom, Mark S., Thelma S. Angeles, Jean Husten, et al.. (2010). Fused bicyclic derivatives of 2,4-diaminopyrimidine as c-Met inhibitors. Bioorganic & Medicinal Chemistry Letters. 21(1). 164–167. 22 indexed citations

13.

Mesaros, Eugen F., Jason P. Burke, Jonathan D. Parrish, et al.. (2010). Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse models. Bioorganic & Medicinal Chemistry Letters. 21(1). 463–466. 27 indexed citations

14.

Zificsak, Craig A., Jay Theroff, Lisa D. Aimone, et al.. (2010). 2,4-Diaminopyrimidine inhibitors of c-Met kinase bearing benzoxazepine anilines. Bioorganic & Medicinal Chemistry Letters. 21(2). 660–663. 13 indexed citations

15.

Underiner, Ted L., Bruce Ruggeri, Lisa D. Aimone, et al.. (2008). TIE-2/VEGF-R2 SAR and in vitro activity of C3-acyl dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole analogs. Bioorganic & Medicinal Chemistry Letters. 18(7). 2368–2372. 8 indexed citations

16.

Zulli, Allison L., Edward R. Bacon, Ted L. Underiner, et al.. (2008). Design and synthesis of dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole oximes as potent dual inhibitors of TIE-2 and VEGF-R2 receptor tyrosine kinases. Bioorganic & Medicinal Chemistry Letters. 18(6). 1916–1921. 15 indexed citations

17.

Ruggeri, Bruce, Ted L. Underiner, Diane E. Gingrich, et al.. (2007). CEP-11981: A potent TIE-2/Pan-VEGF-R inhibitor with broad kinase inhibitory activity exhibits significant antitumor and antiangiogenic efficacy in preclinical tumor models. Molecular Cancer Therapeutics. 6. 2 indexed citations

18.

Zulli, Allison L., Thelma S. Angeles, Shi Yang, et al.. (2006). Novel C-3 N-urea, amide, and carbamate dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole analogs as potent TIE-2 and VEGF-R2 dual inhibitors. Bioorganic & Medicinal Chemistry Letters. 16(20). 5368–5372. 13 indexed citations

19.

Tripathy, Rabindranath, Mohamed Iqbal, J. B. Singh, et al.. (2006). Structure-guided identification of novel VEGFR-2 kinase inhibitors via solution phase parallel synthesis. Bioorganic & Medicinal Chemistry Letters. 16(8). 2158–2162. 88 indexed citations

20.

Tripathy, Rabindranath, Arup K. Ghose, J. B. Singh, et al.. (2006). 1,2,3-Thiadiazole substituted pyrazolones as potent KDR/VEGFR-2 kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 17(6). 1793–1798. 79 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact